Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
The Pharma Letter13h
Duo join Nura Bio’s quest in neurological diseases
Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological ...
Nura Bio Expands Leadership Team with C-Suite Appointments
Nura Bio, Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced today the ...
Yahoo Finance5d
Amylyx Pharmaceuticals, Inc. (AMLX)
After hours: February 14 at 6:51:43 PM EST Loading Chart for AMLX ...
pharmaphorum2d
Amylyx ALS drug draws criticism over $158,000 price tag
Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day ...